View in EDS

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
Authors: Alberer, Martin, Gnad-Vogt, Ulrike, Henoch Sangjoon Hong, Mehr, Keyvan Tadjalli, Backert, Linus, Finak, Greg, Gottardo, Raphael, Bica, Mihai Alexandru, Garofano, Aurelio, Koch, Sven Dominik, Fotin-Mleczek, Mariola, Hoerr, Ingmar, Clemens, Ralf, von Sonnenburg, Frank, Hong, Henoch Sangjoon (AUTHOR)
Source: Lancet. 9/23/2017, Vol. 390 Issue 10101, p1511-1520. 10p. 1 Diagram, 3 Charts, 2 Graphs.
Subjects: Messenger RNA, Rabies vaccines, Antigens, Glycoproteins, Intramuscular injections, Rabies prevention, Clinical trials, Comparative studies, Drug administration, Drug side effects, Immunoglobulins, Longitudinal method, Research methodology, Medical cooperation, Research, RNA, Viral antibodies, Evaluation research, Blind experiment
Geographic Terms: Germany
Abstract: Background: Vaccines based on mRNA coding for antigens have been shown to be safe and immunogenic in preclinical models. We aimed to report results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding rabies virus glycoprotein (CV7201).Methods: We did an open-label, uncontrolled, prospective, phase 1 clinical trial at one centre in Munich, Germany. Healthy male and female volunteers (aged 18-40 years) with no history of rabies vaccination were sequentially enrolled. They received three doses of CV7201 intradermally or intramuscularly by needle-syringe or one of three needle-free devices. Escalating doses were given to subsequent cohorts, and one cohort received a booster dose after 1 year. The primary endpoint was safety and tolerability. The secondary endpoint was to determine the lowest dose of CV7201 to elicit rabies virus neutralising titres equal to or greater than the WHO-specified protective antibody titre of 0·5 IU/mL. The study is continuing for long-term safety and immunogenicity follow-up. This trial is registered with ClinicalTrials.gov, number NCT02241135.Findings: Between Oct 21, 2013, and Jan 11, 2016, we enrolled and vaccinated 101 participants with 306 doses of mRNA (80-640 μg) by needle-syringe (18 intradermally and 24 intramuscularly) or needle-free devices (46 intradermally and 13 intramuscularly). In the 7 days post vaccination, 60 (94%) of 64 intradermally vaccinated participants and 36 (97%) of 37 intramuscularly vaccinated participants reported solicited injection site reactions, and 50 (78%) of 64 intradermally vaccinated participants and 29 (78%) of 37 intramuscularly vaccinated participants reported solicited systemic adverse events, including ten grade 3 events. One unexpected, possibly related, serious adverse reaction that occurred 7 days after a 640 μg intramuscular dose resolved without sequelae. mRNA vaccination by needle-free intradermal or intramuscular device injection induced virus neutralising antibody titres of 0·5 IU/mL or more across dose levels and schedules in 32 (71%) of 45 participants given 80 μg or 160 μg CV7201 doses intradermally and six (46%) of 13 participants given 200 μg or 400 μg CV7201 doses intramuscularly. 1 year later, eight (57%) of 14 participants boosted with an 80 μg needle-free intradermal dose of CV7201 achieved titres of 0·5 IU/mL or more. Conversely, intradermal or intramuscular needle-syringe injection was ineffective, with only one participant (who received 320 μg intradermally) showing a detectable immune response.Interpretation: This first-ever demonstration in human beings shows that a prophylactic mRNA-based candidate vaccine can induce boostable functional antibodies against a viral antigen when administered with a needle-free device, although not when injected by a needle-syringe. The vaccine was generally safe with a reasonable tolerability profile.Funding: CureVac AG. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 125412336
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Alberer%2C+Martin%22">Alberer, Martin</searchLink><br /><searchLink fieldCode="AR" term="%22Gnad-Vogt%2C+Ulrike%22">Gnad-Vogt, Ulrike</searchLink><br /><searchLink fieldCode="AR" term="%22Henoch+Sangjoon+Hong%22">Henoch Sangjoon Hong</searchLink><br /><searchLink fieldCode="AR" term="%22Mehr%2C+Keyvan+Tadjalli%22">Mehr, Keyvan Tadjalli</searchLink><br /><searchLink fieldCode="AR" term="%22Backert%2C+Linus%22">Backert, Linus</searchLink><br /><searchLink fieldCode="AR" term="%22Finak%2C+Greg%22">Finak, Greg</searchLink><br /><searchLink fieldCode="AR" term="%22Gottardo%2C+Raphael%22">Gottardo, Raphael</searchLink><br /><searchLink fieldCode="AR" term="%22Bica%2C+Mihai+Alexandru%22">Bica, Mihai Alexandru</searchLink><br /><searchLink fieldCode="AR" term="%22Garofano%2C+Aurelio%22">Garofano, Aurelio</searchLink><br /><searchLink fieldCode="AR" term="%22Koch%2C+Sven+Dominik%22">Koch, Sven Dominik</searchLink><br /><searchLink fieldCode="AR" term="%22Fotin-Mleczek%2C+Mariola%22">Fotin-Mleczek, Mariola</searchLink><br /><searchLink fieldCode="AR" term="%22Hoerr%2C+Ingmar%22">Hoerr, Ingmar</searchLink><br /><searchLink fieldCode="AR" term="%22Clemens%2C+Ralf%22">Clemens, Ralf</searchLink><br /><searchLink fieldCode="AR" term="%22von+Sonnenburg%2C+Frank%22">von Sonnenburg, Frank</searchLink><br /><searchLink fieldCode="AR" term="%22Hong%2C+Henoch+Sangjoon%22">Hong, Henoch Sangjoon</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 9/23/2017, Vol. 390 Issue 10101, p1511-1520. 10p. 1 Diagram, 3 Charts, 2 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Messenger+RNA%22">Messenger RNA</searchLink><br /><searchLink fieldCode="DE" term="%22Rabies+vaccines%22">Rabies vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22Antigens%22">Antigens</searchLink><br /><searchLink fieldCode="DE" term="%22Glycoproteins%22">Glycoproteins</searchLink><br /><searchLink fieldCode="DE" term="%22Intramuscular+injections%22">Intramuscular injections</searchLink><br /><searchLink fieldCode="DE" term="%22Rabies+prevention%22">Rabies prevention</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+administration%22">Drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+side+effects%22">Drug side effects</searchLink><br /><searchLink fieldCode="DE" term="%22Immunoglobulins%22">Immunoglobulins</searchLink><br /><searchLink fieldCode="DE" term="%22Longitudinal+method%22">Longitudinal method</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22RNA%22">RNA</searchLink><br /><searchLink fieldCode="DE" term="%22Viral+antibodies%22">Viral antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Blind+experiment%22">Blind experiment</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Germany%22">Germany</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Vaccines based on mRNA coding for antigens have been shown to be safe and immunogenic in preclinical models. We aimed to report results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding rabies virus glycoprotein (CV7201).<bold>Methods: </bold>We did an open-label, uncontrolled, prospective, phase 1 clinical trial at one centre in Munich, Germany. Healthy male and female volunteers (aged 18-40 years) with no history of rabies vaccination were sequentially enrolled. They received three doses of CV7201 intradermally or intramuscularly by needle-syringe or one of three needle-free devices. Escalating doses were given to subsequent cohorts, and one cohort received a booster dose after 1 year. The primary endpoint was safety and tolerability. The secondary endpoint was to determine the lowest dose of CV7201 to elicit rabies virus neutralising titres equal to or greater than the WHO-specified protective antibody titre of 0·5 IU/mL. The study is continuing for long-term safety and immunogenicity follow-up. This trial is registered with ClinicalTrials.gov, number NCT02241135.<bold>Findings: </bold>Between Oct 21, 2013, and Jan 11, 2016, we enrolled and vaccinated 101 participants with 306 doses of mRNA (80-640 μg) by needle-syringe (18 intradermally and 24 intramuscularly) or needle-free devices (46 intradermally and 13 intramuscularly). In the 7 days post vaccination, 60 (94%) of 64 intradermally vaccinated participants and 36 (97%) of 37 intramuscularly vaccinated participants reported solicited injection site reactions, and 50 (78%) of 64 intradermally vaccinated participants and 29 (78%) of 37 intramuscularly vaccinated participants reported solicited systemic adverse events, including ten grade 3 events. One unexpected, possibly related, serious adverse reaction that occurred 7 days after a 640 μg intramuscular dose resolved without sequelae. mRNA vaccination by needle-free intradermal or intramuscular device injection induced virus neutralising antibody titres of 0·5 IU/mL or more across dose levels and schedules in 32 (71%) of 45 participants given 80 μg or 160 μg CV7201 doses intradermally and six (46%) of 13 participants given 200 μg or 400 μg CV7201 doses intramuscularly. 1 year later, eight (57%) of 14 participants boosted with an 80 μg needle-free intradermal dose of CV7201 achieved titres of 0·5 IU/mL or more. Conversely, intradermal or intramuscular needle-syringe injection was ineffective, with only one participant (who received 320 μg intradermally) showing a detectable immune response.<bold>Interpretation: </bold>This first-ever demonstration in human beings shows that a prophylactic mRNA-based candidate vaccine can induce boostable functional antibodies against a viral antigen when administered with a needle-free device, although not when injected by a needle-syringe. The vaccine was generally safe with a reasonable tolerability profile.<bold>Funding: </bold>CureVac AG. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=125412336
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(17)31665-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 1511
    Subjects:
      – SubjectFull: Messenger RNA
        Type: general
      – SubjectFull: Rabies vaccines
        Type: general
      – SubjectFull: Antigens
        Type: general
      – SubjectFull: Glycoproteins
        Type: general
      – SubjectFull: Intramuscular injections
        Type: general
      – SubjectFull: Rabies prevention
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Drug administration
        Type: general
      – SubjectFull: Drug side effects
        Type: general
      – SubjectFull: Immunoglobulins
        Type: general
      – SubjectFull: Longitudinal method
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: RNA
        Type: general
      – SubjectFull: Viral antibodies
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Blind experiment
        Type: general
      – SubjectFull: Germany
        Type: general
    Titles:
      – TitleFull: Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Alberer, Martin
      – PersonEntity:
          Name:
            NameFull: Gnad-Vogt, Ulrike
      – PersonEntity:
          Name:
            NameFull: Henoch Sangjoon Hong
      – PersonEntity:
          Name:
            NameFull: Mehr, Keyvan Tadjalli
      – PersonEntity:
          Name:
            NameFull: Backert, Linus
      – PersonEntity:
          Name:
            NameFull: Finak, Greg
      – PersonEntity:
          Name:
            NameFull: Gottardo, Raphael
      – PersonEntity:
          Name:
            NameFull: Bica, Mihai Alexandru
      – PersonEntity:
          Name:
            NameFull: Garofano, Aurelio
      – PersonEntity:
          Name:
            NameFull: Koch, Sven Dominik
      – PersonEntity:
          Name:
            NameFull: Fotin-Mleczek, Mariola
      – PersonEntity:
          Name:
            NameFull: Hoerr, Ingmar
      – PersonEntity:
          Name:
            NameFull: Clemens, Ralf
      – PersonEntity:
          Name:
            NameFull: von Sonnenburg, Frank
      – PersonEntity:
          Name:
            NameFull: Hong, Henoch Sangjoon
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 09
              Text: 9/23/2017
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 390
            – Type: issue
              Value: 10101
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1